Accumulation and activation of CD4+FoxP3+ Tregs acts as a dominant immune escape mechanism for gliomas and underline the importance of controlling tumor-infiltrating Tregs in glioma immunotherapy. The gene discussed is CD4; the disease is central nervous system cancer.